Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Cyclic peptides constitute an important drug modality since they offer significant advantages over small molecules and macromolecules. However, access to diverse chemical sets of cyclic peptides is difficult on a large library scale. DNA-encoded Chemical Libraries (DELs) provide a suitable tool to obtain large chemical diversity, but cyclic DELs made by standard DEL implementation cannot efficiently explore their conformational diversity. On the other hand, dual-display Encoded Self-Assembling Chemical (ESAC) Libraries can be used for modulating macrocycle flexibility since the two displayed peptides can be connected in an incremental fashion. In this work, we construct a 56 million dual-display ESAC library using a two-step cyclization strategy. We show that varying the level of conformational restraint is essential for the discovery of specific ligands for the three protein targets thrombin, human alkaline phosphatase and streptavidin.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11972359 | PMC |
| http://dx.doi.org/10.1038/s41467-025-58507-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Developing Methods for the Synthesis of Ligand-Oligonucleotide Conjugates for Drug Discovery Applications.
Chem Pharm Bull (Tokyo)
August 2025
Graduate School of Pharmaceutical Sciences, The University of Osaka.
Recently, oligonucleotide-based drug discovery has attracted considerable amounts of attention. As oligonucleotide therapeutics have evolved into practical use, research into the development of functional artificial nucleic acids has been vigorously conducted worldwide. However, the synthesis of artificial nucleic acids generally requires long sequences from starting materials; hence, structurally optimizing oligonucleotide therapeutics is extremely difficult.
View Article and Find Full Text PDFDiscovery of RNA-Targeting Small Molecules: Challenges and Future Directions.
MedComm (2020)
September 2025
DP Technology Beijing China.
RNA-targeting small molecules represent a transformative frontier in drug discovery, offering novel therapeutic avenues for diseases traditionally deemed undruggable. This review explores the latest advancements in the development of RNA-binding small molecules, focusing on the current obstacles and promising avenues for future research. We highlight innovations in RNA structure determination, including X-ray crystallography, nuclear magnetic resonance spectroscopy, and cryo-electron microscopy, which provide the foundation for rational drug design.
View Article and Find Full Text PDFIn Situ Click Chemistry Screen Facilitated by an On-Nanoparticle DNA-Encoded Library Identifies Highly Selective and Potent Peptoid Ligands for a Phosphatase.
Angew Chem Int Ed Engl
August 2025
Department of Chemistry and Division of Advanced Materials Science, Pohang University of Science and Technology (POSTECH), Pohang, 37673, South Korea.
Capture agents that selectively bind to biological targets are indispensable tools in diagnostics, therapeutics, and biomedical research. However, discovering such capture agents, particularly for structurally conserved or challenging targets, remains a challenge. Here, we describe a protein-templated in situ click strategy enabled by a nanoparticle-based DNA-encoded library (nanoDEL) platform.
View Article and Find Full Text PDFOn-DNA Synthesis of Privileged Dihydropteridinones via Diboron-Mediated Cyclizations.
Org Lett
September 2025
State Key Laboratory of Drug Research, Shanghai Institute of MateriaMedica, Chinese Academy of Sciences, Shanghai 201203, P. R. China.
DNA-encoded chemical library (DECL) technology has emerged as a pivotal platform for high-throughput screening in drug discovery. Expanding the chemical space of DECLs requires the development of novel, robust, and DNA-compatible transformations, with atom-economical cyclizations being particularly attractive for generating drug-like scaffolds. The 7,8-dihydropteridinone core represents a pharmacologically important heterocycle whose incorporation into DECLs has been hampered by harsh synthetic conditions.
View Article and Find Full Text PDFDiscovery and Optimization of LAG-3-Targeted Small Molecules via DNA-Encoded Chemical Library (DEL) Screening for Cancer Immunotherapy.
J Med Chem
August 2025
Department of Radiology, Molecular Imaging Innovations Institute (MI3), Weill Cornell Medicine, New York, New York 10065, United States.
Lymphocyte activation gene-3 protein (LAG-3) is an immune checkpoint receptor that promotes T cell exhaustion and immune evasion in cancer. While antibody-based LAG-3 inhibitors have reached the clinic, small molecule modulators remain unexplored. Here, we report compound , the most potent small molecule LAG-3 inhibitor to date.
View Article and Find Full Text PDF